Arndt Vogel· @ArndtVogel · X·· 15 小时前评分70
正文 · 机器翻译
QTX3034（一种口服 G12D 偏好型 KRAS 抑制剂）联合 cetuximab ± mFOLFOX6 治疗 KRASG12D-mCRC 的初步临床结果
#ESMO26 #ESMOAmbassadors
👉ORR：25% vs 50%，DCR：75 vs 90%
👉未发现新的安全性信号
🧐支持与 CTx 联用
@myESMO @ASCO
224 浏览 · 3 赞 · 3 转发 · 0 回复
会议摘要
788RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上
Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.orgNCT06578559NCT06578559按 - **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC 对上
- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.orgNCT06640166NCT06640166按 - **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. 对上
- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：Arndt Vogel · x.com